Loading clinical trials...

Financial Incentives to Increase Pediatric HIV Testing | Clinical Trials | Clareo Health

COMPLETEDNA

Financial Incentives to Increase Pediatric HIV Testing

NCT03049917•University of Washington

Summary

The purpose of this study is to determine whether giving small financial incentives will motivate parents to test their children for HIV.

Detailed Description

The study will be a randomized controlled trial (RCT) with 5 arms with equal allocation to each arm: no incentive, or one of 4 different levels of financial incentive. We will randomize 800 parents with children of unknown status at HIV treatment clinics in Western Kenya.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Parent/caregiver receiving HIV care
•Parent/caregiver has one or more children \<13 years old
•Child is HIV exposed (parent/caregiver report or clinic confirmation)
•Caregiver reports child's HIV status is unknown

Exclusion Criteria

•None
•* The investigators reserve the right to exclude any potential enrollee who is deemed to be at high personal risk, or whose children are at high personal risk, of interpersonal violence, by study participation .

Locations (1)

Kisumu County Hospital

Kisumu, Kenya

Key Dates

Start Date

February 6, 2017

Primary Completion Date

October 1, 2018

Completion Date

October 1, 2018

Last Updated

June 25, 2021

Enrollment

452

ACTUAL participants

Conditions

HIV

Interventions

Financial incentive

BEHAVIORAL

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

NCT04929028

View study

RECRUITINGPHASE3

A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)

NCT07071623

Human Immunodeficiency Virus (HIV)HIV Pre-Exposure Prophylaxis

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 25, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Financial Incentives to Increase Pediatric HIV Testing

Inclusion Criteria

Exclusion Criteria

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)

Thinking and Memory Problems in People With HIV

The LD Lync Study - Natural History Study of Lipodystrophy Syndromes

Long-acting Cabotegravir Injectable Pre-exposure Prophylaxis for People Who Inject Drugs

Imaging and Biopsy of People With HIV-1 Undergoing Analytic Treatment Interruption